Prelude Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Prelude Therapeutics Incorporated

16/03/2022 12:38

* Prelude Therapeutics Inc  PRLD.OQ  reported a quarterly
adjusted
loss of 71 cents​​ per share for the quarter ended in December.
The mean expectation of four analysts for the quarter was for a
loss of 68 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Prelude Therapeutics Inc's reported EPS for the quarter
was a
loss of 71 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Prelude Therapeutics Inc shares had fallen by 42.6% this
quarter.
    * The company reported a quarterly loss of $32.84 million.
    * Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $15.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 16 at 12:37 p.m.  ​All
figures in US dollars unless otherwise stated